Sanofi licenses new CRISPR enzyme from startup Scribe, STAT reports

Sanofi will pay startup Scribe Therapeutics $40M upfront and promise another $1.2B in potential milestones to license a DNA-cutting enzyme, called CasX, for use in a potential single-infusion treatment for “a safer, simpler and more scalable cure” for sickle cell disease, reported STAT News’ Jason Mast. Sanofi planned to announce the news Tuesday, but it was published early Monday by GEN, according to STAT.